Literature DB >> 30524894

IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge.

Xinchun Zheng1, Yang Zhou1, Xuan Yi1, Chengcong Chen1, Chunhua Wen1, Guofu Ye1, Xiaoyi Li1, Libo Tang1, Xiaoyong Zhang1, Fuqiang Yang2, Guangze Liu2, Yongyin Li1, Jinlin Hou1.   

Abstract

Hepatocellular carcinoma (HCC) is a typical inflammation-associated cancer. IL-21 regulates both innate and adaptive immune responses and has key roles in antitumor and antiviral responses. However, the role of IL-21 in HCC development is poorly defined. In the current study, we explored the role of IL-21R signaling in HCC growth by using IL-21R knockout mice and HCC mouse models. We discovered that IL-21R signaling deficiency promoted HCC growth in tumor-bearing mice. We showed that IL-21R deletion reduced T cells infiltration and activation as well as their function but increased the accumulation of myeloid-derived suppressor cells in tumor tissues to enhance HCC growth. Furthermore, loss of IL-21R signaling in tumor-bearing mice resulted in an imbalance of the systemic immune system characterized by decreased antitumor immune cells and increased immunosuppressive cells in the spleen and lymph nodes. In addition, we revealed that IL-21R signaling is critical for the expansion of antitumor immune cells in the memory immune response to tumor rechallenge. Finally, we showed that the transcriptional levels of IL-21 in the peritumoral region and IL-21R within the tumor are associated with survival and recurrence of HCC patients. In conclusion, our study demonstrates that IL-21R signaling is essential for controlling the development of HCC and immunological memory response to tumor challenge.

Entities:  

Keywords:  HCC; IL-21 receptor; immune memory response; mouse HCC model; tumor-specific immune response

Year:  2018        PMID: 30524894      PMCID: PMC6279328          DOI: 10.1080/2162402X.2018.1500673

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  47 in total

1.  IL-21 induces the apoptosis of resting and activated primary B cells.

Authors:  Devangi S Mehta; Andrea L Wurster; Matthew J Whitters; Deborah A Young; Mary Collins; Michael J Grusby
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.

Authors:  Andrew L Rankin; Heath Guay; Deborah Herber; Sarah A Bertino; Tatyana A Duzanski; Yijun Carrier; Sean Keegan; Mayra Senices; Nancy Stedman; Mark Ryan; Laird Bloom; Quintus Medley; Mary Collins; Cheryl Nickerson-Nutter; Joe Craft; Deborah Young; Kyri Dunussi-Joannopoulos
Journal:  J Immunol       Date:  2012-01-09       Impact factor: 5.422

3.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

4.  Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses.

Authors:  Brianne R Barker; Michael N Gladstone; Geoffrey O Gillard; Michael W Panas; Norman L Letvin
Journal:  Eur J Immunol       Date:  2010-10-27       Impact factor: 5.532

5.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Authors:  Suresh Kalathil; Amit A Lugade; Austin Miller; Renuka Iyer; Yasmin Thanavala
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

6.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.

Authors:  Kristopher A Sarosiek; Raquel Malumbres; Hovav Nechushtan; Andrew J Gentles; Eli Avisar; Izidore S Lossos
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

7.  IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Authors:  Emma Di Carlo; Alberto Comes; Anna Maria Orengo; Ombretta Rosso; Raffaella Meazza; Piero Musiani; Mario P Colombo; Silvano Ferrini
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  IL-21R signaling is critical for induction of spontaneous experimental autoimmune encephalomyelitis.

Authors:  Youjin Lee; Meike Mitsdoerffer; Sheng Xiao; Guangxiang Gu; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Clin Invest       Date:  2015-09-28       Impact factor: 14.808

9.  In vivo antitumor activity of interleukin 21 mediated by natural killer cells.

Authors:  Gang Wang; Mary Tschoi; Rosanne Spolski; Yanyan Lou; Katsutoshi Ozaki; Chiguang Feng; Grace Kim; Warren J Leonard; Patrick Hwu
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

10.  Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis.

Authors:  Veronica De Simone; Giulia Ronchetti; Eleonora Franzè; Alfredo Colantoni; Angela Ortenzi; Massimo C Fantini; Angelamaria Rizzo; Giuseppe S Sica; Pierpaolo Sileri; Piero Rossi; Thomas T MacDonald; Francesco Pallone; Giovanni Monteleone; Carmine Stolfi
Journal:  Oncotarget       Date:  2015-04-30
View more
  2 in total

Review 1.  Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.

Authors:  Antonio Pecoraro; Ludovica Crescenzi; Gilda Varricchi; Giancarlo Marone; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

2.  Targeting Cbx3/HP1γ Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence.

Authors:  Phuong T Le; Ngoc Ha; Ngan K Tran; Andrew G Newman; Katharine M Esselen; John L Dalrymple; Eva M Schmelz; Avinash Bhandoola; Hai-Hui Xue; Prim B Singh; To-Ha Thai
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.